Currently Viewing:
Newsroom
Currently Reading
Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds
January 20, 2018 – Laura Joszt
Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access
January 19, 2018 – Mary Caffrey
Long-Term Oral Contraceptive Use Associated With Reduced Risk of Ovarian, Endometrial Cancer
January 19, 2018 – Jaime Rosenberg
This Week in Managed Care: January 19, 2018
January 19, 2018
Wearable Biosensors Have No Significant Impact on Clinical Outcomes
January 19, 2018 – Kaitlynn Ely
Proposed Drug to Treat Oculopharyngeal Muscular Dystrophy Gains Orphan Drug Designation
January 19, 2018 – Kelly Davio
What We're Reading: House Passes CHIP Funding; Cancer Blood Test; Drug Policy Office Budget
January 19, 2018 – AJMC Staff
AJMC® in the Press, January 19, 2018
January 19, 2018 – AJMC Staff
Risk-Targeted Lung Cancer Screening Shows Modest Benefits
January 19, 2018 – Samantha DiGrande

FDA Panel Wants More Data for Astra's Olaparib

Safety concerns over the PARP inhibitor warranted the request for additional data.
An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.

The panel voted 11-2 that the company should complete a second trial to confirm results seen in a smaller study which, while positive, were not robust enough to convince the committee that they could be reproduced. Panel members expressed concern about a potential increased risk of secondary cancers in patients receiving the drug, olaparib, as well as side effects such as nausea and gastrointestinal disturbances.

The FDA is not obliged to follow the advice of its advisory panels but typically does so. Olaparib is one of several cancer drugs AstraZeneca flagged as having strong potential in its defense of a $118 billion take-over bid by Pfizer Inc.

Original report: http://reut.rs/1mfMHCT

Source: Reuters

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!